Epilepsy & Seizure Disorders

Filter Your Results

 

News

 

Briviact Approved as Monotherapy for Partial-Onset Seizures

Friday, September 15, 2017—The FDA has approved a supplemental new drug application for Briviact (brivaracetam, UCB) CV as monotherapy for partial-onset (focal) seizures (POS) in patients 16 y…

Aptiom Approved for Partial-Onset Seizures in Patients Four Years of Age and Older

Thursday, September 14, 2017—The FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Aptiom (eslicarbazepine acetate, Sunovion) to include treatment of partial-…

SUDEP: Risk Factors and Proposed Mechanisms

Michelle L. Dougherty, MD

July/August 2017—Patients and families deserve information about their risk for SUDEP and steps that can be taken to minimize that risk.

VNS Therapy Approved in Children Ages Four Years and Older with Partial Onset Refractory Seizures

Friday, June 30, 2017—The FDA has approved the VNS Therapy (LivaNova) in patients as young as four years of age with partial onset refractory seizures. Originally approved for patients ages 12…

Low-Dose Fenfluramine Granted Orphan Status for LGS

Tuesday, June 27, 2017—The FDA has granted orphan drug designation to ZX008 (Zogenix), an investigational treatment for Lennox Gastaut Syndrome (LGS). Zogenix will initiate a Phase 3 clinical trial …

American Epilepsy Society Awards Investigators for Early Career Research

Monday, June 12, 2017—The American Epilepsy Society (AES) has awarded 25 early career scientists and clinicians with fellowships or grants to support their work in epilepsy research. The award reci…

NEJM Publishes Phase 3 Data for Epidiolex in Dravet Syndrome as Manufacturer Eyes Mid-2017 NDA Submission

Friday, May 26, 2017—The New England Journal of Medicine has published results from a Phase 3 study showing that Epidiolex (cannabidiol, GW Pharmaceuticals) reduces monthly convulsive seizure freq…

New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures

Wednesday, May 03, 2017—Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of Ne…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC